- Home
- KEYS vs REGN Comparison
KEYS vs REGN Comparison
Compare KEYS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KEYS | REGN |
|---|---|---|
| Founded | 1939 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3B | 68.8B |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | KEYS | REGN |
|---|---|---|
| Price | $352.16 | $791.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 25 |
| Target Price | $287.00 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 1.1M | 764.3K |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | ★ 39.89 | 8.19 |
| EPS | 3.64 | ★ 18.95 |
| Revenue | $5,375,000,000.00 | ★ $5,872,227,000.00 |
| Revenue This Year | $25.49 | $12.45 |
| Revenue Next Year | $8.17 | $10.13 |
| P/E Ratio | $94.42 | ★ $42.06 |
| Revenue Growth | 7.95 | ★ 20.82 |
| 52 Week Low | $152.85 | $541.00 |
| 52 Week High | $374.96 | $821.11 |
Technical Indicators
Market Signals| Indicator | KEYS | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 72.58 |
| Support Level | $322.97 | $738.17 |
| Resistance Level | $368.23 | $818.06 |
| Average True Range (ATR) | 10.93 | 21.24 |
| MACD | 4.21 | 6.97 |
| Stochastic Oscillator | 96.74 | 83.50 |
Price Performance
Historical ComparisonAbout KEYS Keysight Technologies Inc.
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.